P1–362: Amyloid PET screening results by APOE‐ε4 status from a phase 1b clinical study of 221AD103 in people with prodromal to mild Alzheimer's disease
Ping Chiao(Biogen (United States)), Jeff Sevigny(Ovid Therapeutics (United States)), Joyce Suhy(BioClinica (United States)), Jerome Barakos(Sutter Health), Meredith Burke(Syntek Technologies (United States)), Gregory Klein(Roche (Switzerland))
Cited by 1
Related Papers
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
|Neurology|2009|741
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
|The Lancet Neurology|2010|696
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
|JAMA Neurology|2021|602
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
|Alzheimer s Research & Therapy|2017|568